Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma

ABSTRACT We report the case of a 76‐year‐old woman with refractory immune thrombocytopenia (ITP) and multiple myeloma (MM) who achieved remission of both conditions following teclistamab treatment. After failing multiple ITP therapies, her platelet count continued to decline. Initiation of teclistam...

Full description

Saved in:
Bibliographic Details
Main Authors: Renata Quevedo‐Salazar, José Miguel Yáñez‐Reyes, Elías Eugenio González‐López, Ana Varela‐Constantino, Andrés Gómez‐De León, Xitlaly Judith González‐Leal, David Gómez‐Almaguer
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:eJHaem
Online Access:https://doi.org/10.1002/jha2.70062
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849685392955015168
author Renata Quevedo‐Salazar
José Miguel Yáñez‐Reyes
Elías Eugenio González‐López
Ana Varela‐Constantino
Andrés Gómez‐De León
Xitlaly Judith González‐Leal
David Gómez‐Almaguer
author_facet Renata Quevedo‐Salazar
José Miguel Yáñez‐Reyes
Elías Eugenio González‐López
Ana Varela‐Constantino
Andrés Gómez‐De León
Xitlaly Judith González‐Leal
David Gómez‐Almaguer
author_sort Renata Quevedo‐Salazar
collection DOAJ
description ABSTRACT We report the case of a 76‐year‐old woman with refractory immune thrombocytopenia (ITP) and multiple myeloma (MM) who achieved remission of both conditions following teclistamab treatment. After failing multiple ITP therapies, her platelet count continued to decline. Initiation of teclistamab led to a rapid and sustained platelet increase, alongside MM response with measurable residual disease (MRD) negativity. Notably, remission was achieved after only four full doses, and the patient has remained in complete remission since. This case highlights teclistamab as a potential treatment for refractory ITP, suggesting a novel role for B‐cell maturation antigen (BCMA)‐targeted therapies in autoimmune diseases. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.
format Article
id doaj-art-43682128eb004f24a80e21de3effdb85
institution DOAJ
issn 2688-6146
language English
publishDate 2025-06-01
publisher Wiley
record_format Article
series eJHaem
spelling doaj-art-43682128eb004f24a80e21de3effdb852025-08-20T03:23:08ZengWileyeJHaem2688-61462025-06-0163n/an/a10.1002/jha2.70062Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple MyelomaRenata Quevedo‐Salazar0José Miguel Yáñez‐Reyes1Elías Eugenio González‐López2Ana Varela‐Constantino3Andrés Gómez‐De León4Xitlaly Judith González‐Leal5David Gómez‐Almaguer6Tecnologico de Monterrey Internal Medicine, Monterrey Nuevo Leon MexicoHospital Universitario Dr. Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Hematology Monterrey Nuevo Leon MexicoClinica Gomez Almaguer, Hematology Monterrey Nuevo Leon MexicoClinica Gomez Almaguer, Hematology Monterrey Nuevo Leon MexicoClinica Gomez Almaguer, Hematology Monterrey Nuevo Leon MexicoTecnologico de Monterrey Internal Medicine, Monterrey Nuevo Leon MexicoClinica Gomez Almaguer, Hematology Monterrey Nuevo Leon MexicoABSTRACT We report the case of a 76‐year‐old woman with refractory immune thrombocytopenia (ITP) and multiple myeloma (MM) who achieved remission of both conditions following teclistamab treatment. After failing multiple ITP therapies, her platelet count continued to decline. Initiation of teclistamab led to a rapid and sustained platelet increase, alongside MM response with measurable residual disease (MRD) negativity. Notably, remission was achieved after only four full doses, and the patient has remained in complete remission since. This case highlights teclistamab as a potential treatment for refractory ITP, suggesting a novel role for B‐cell maturation antigen (BCMA)‐targeted therapies in autoimmune diseases. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.https://doi.org/10.1002/jha2.70062
spellingShingle Renata Quevedo‐Salazar
José Miguel Yáñez‐Reyes
Elías Eugenio González‐López
Ana Varela‐Constantino
Andrés Gómez‐De León
Xitlaly Judith González‐Leal
David Gómez‐Almaguer
Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma
eJHaem
title Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma
title_full Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma
title_fullStr Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma
title_full_unstemmed Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma
title_short Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma
title_sort teclistamab induced remission of chronic immune thrombocytopenia in a patient with multiple myeloma
url https://doi.org/10.1002/jha2.70062
work_keys_str_mv AT renataquevedosalazar teclistamabinducedremissionofchronicimmunethrombocytopeniainapatientwithmultiplemyeloma
AT josemiguelyanezreyes teclistamabinducedremissionofchronicimmunethrombocytopeniainapatientwithmultiplemyeloma
AT eliaseugeniogonzalezlopez teclistamabinducedremissionofchronicimmunethrombocytopeniainapatientwithmultiplemyeloma
AT anavarelaconstantino teclistamabinducedremissionofchronicimmunethrombocytopeniainapatientwithmultiplemyeloma
AT andresgomezdeleon teclistamabinducedremissionofchronicimmunethrombocytopeniainapatientwithmultiplemyeloma
AT xitlalyjudithgonzalezleal teclistamabinducedremissionofchronicimmunethrombocytopeniainapatientwithmultiplemyeloma
AT davidgomezalmaguer teclistamabinducedremissionofchronicimmunethrombocytopeniainapatientwithmultiplemyeloma